G Haidar1, M Crespo2, S Maximous2, E Lendermon2, C J Clancy3, M H Nguyen2. 1. Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. Electronic address: haidarg@upmc.edu. 2. Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. 3. Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA; VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania, USA.
Abstract
INTRODUCTION: The association between belatacept, a CD28 costimulation blocker, and invasive mycoses is unclear. CASE REPORT: We describe a patient who initiated belatacept 3 years after lung transplantation and developed invasive tracheobronchial aspergillosis, a disease encountered almost exclusively within the first 6 months after transplantation. CONCLUSIONS: Belatacept may have played a causative role. Until more data are available, belatacept should be used cautiously after lung transplantation.
INTRODUCTION: The association between belatacept, a CD28 costimulation blocker, and invasive mycoses is unclear. CASE REPORT: We describe a patient who initiated belatacept 3 years after lung transplantation and developed invasive tracheobronchial aspergillosis, a disease encountered almost exclusively within the first 6 months after transplantation. CONCLUSIONS: Belatacept may have played a causative role. Until more data are available, belatacept should be used cautiously after lung transplantation.